PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18250162-8 2008 Furthermore, overexpression of PRX1 protected cells against 6-OHDA-induced activation of p38 MAPK and subsequent activation of caspase-3. Oxidopamine 60-66 caspase 3 Mus musculus 127-136 21846476-4 2011 Treatment of mesencephalic dopaminergic neuronal N27 cells with 6-OHDA (100 muM) for 24h significantly reduced mitochondrial activity and increased cytosolic cytochrome c, followed by sequential activation of caspase-9 and caspase-3. Oxidopamine 64-70 caspase 3 Mus musculus 223-232 21846476-6 2011 Interestingly, 6-OHDA induced proteolytic cleavage and activation of protein kinase C delta (PKCdelta) was completely suppressed by treatment with a caspase-3-specific inhibitor, Z-DEVD-FMK (50 muM). Oxidopamine 15-21 caspase 3 Mus musculus 149-158 21846476-7 2011 Furthermore, expression of caspase-3 cleavage site-resistant mutant PKCdelta(D327A) and kinase dead PKCdelta(K376R) or siRNA-mediated knockdown of PKCdelta protected against 6-OHDA-induced neuronal cell death, suggesting that caspase-3-dependent PKCdelta promotes oxidative stress-induced dopaminergic degeneration. Oxidopamine 174-180 caspase 3 Mus musculus 27-36 29082467-0 2017 Let-7d microRNA Attenuates 6-OHDA-Induced Injury by Targeting Caspase-3 in MN9D Cells. Oxidopamine 27-33 caspase 3 Mus musculus 62-71 29062606-7 2017 Cleaved Poly (ADP-ribose) polymerase-1 (PARP-1) and cleaved caspase-3 were decreased by nicotine in 6-hydroxydopamine (6-OHDA) lesioned mice and in MPP+-treated SH-SY5Y cells. Oxidopamine 100-117 caspase 3 Mus musculus 60-69 29062606-7 2017 Cleaved Poly (ADP-ribose) polymerase-1 (PARP-1) and cleaved caspase-3 were decreased by nicotine in 6-hydroxydopamine (6-OHDA) lesioned mice and in MPP+-treated SH-SY5Y cells. Oxidopamine 119-125 caspase 3 Mus musculus 60-69 27671228-7 2017 Of note, FTY720 retained the phosphorylation of ERK, together with a decreased expression of cleaved caspase-3 in mice treated with 6-OHDA or rotenone. Oxidopamine 132-138 caspase 3 Mus musculus 101-110 23518299-6 2013 In addition, SFN protected 6-OHDA-induced apoptosis via blocking DNA fragmentation and caspase-3 activation. Oxidopamine 27-33 caspase 3 Mus musculus 87-96 17973977-2 2008 Stimulation with glutamate or 6-hydroxy-dopamine caused activation of caspase-3 and apoptotic neuronal death which were both attenuated by JNK-inhibition. Oxidopamine 30-48 caspase 3 Mus musculus 70-79 15596235-5 2005 Furthermore, a high dose of levodopa/carbidopa (50/12.5 mg/kg) enhanced LPO and caspase-3, -8, and -9 activities in 6-OHDA-lesioned mouse brain. Oxidopamine 116-122 caspase 3 Mus musculus 80-101 17895242-3 2007 In vitro studies using the murine dopaminergic cell line MN9D showed that leptin attenuated 6-OHDA-induced apoptotic markers, including caspase-9 and caspase-3 activation, internucleosomal DNA fragmentation, and cytochrome c release. Oxidopamine 92-98 caspase 3 Mus musculus 150-159 17045926-8 2006 Cotreatment of z-DIPD-fmk with the parkinsonian toxins MPP(+) and 6-OHDA dose dependently attenuated cytotoxicity, caspase-3 activation, and DNA fragmentation in a mesencephalic dopaminergic neuronal cell model (N27 cells). Oxidopamine 66-72 caspase 3 Mus musculus 115-124 15596235-6 2005 However, when levodopa/carbidopa (50/12.5 mg/kg) was combined with cabergoline (0.25 mg/kg), the effect reduced levodopa"s enhancement of caspase-3, -8, and -9 activities in the 6-OHDA-lesioned mouse brain. Oxidopamine 178-184 caspase 3 Mus musculus 138-159 15352222-6 2004 These results point to the intrinsic caspase-9/caspase-3 cascade as the predominant signaling pathway underlying dopaminergic cell death induced by 6-OHDA and suggest that gene delivery of caspase-9dn can attenuate this pathway and its degenerative consequences. Oxidopamine 148-154 caspase 3 Mus musculus 47-56 12867415-0 2003 Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson"s disease. Oxidopamine 91-108 caspase 3 Mus musculus 117-126 14993216-10 2004 Co-treatment with PD169316 deterred 6-hydroxydopamine-induced loss of dopaminergic neurons and activation of caspase-3 in these neurons. Oxidopamine 36-53 caspase 3 Mus musculus 109-118 12832530-4 2003 However, the appearance of activated caspase-3 immunoreactivity in tyrosine hydroxylase (TH)-positive neurons was detected only after 6-OHDA. Oxidopamine 134-140 caspase 3 Mus musculus 37-46 12397073-7 2002 Thus, 6-hydroxydopamine fully abolishes the alpha-synuclein-mediated reduction of caspase 3 activity and reverses the associated decrease of p53 expression. Oxidopamine 6-23 caspase 3 Mus musculus 82-91 12397073-9 2002 Altogether, we suggest that alpha-synuclein lowers the p53-dependent caspase 3 activation of TSM1 in response to apoptotic stimuli and we propose that the natural toxin 6-hydroxydopamine abolishes this antiapoptotic phenotype by triggering alpha-synuclein aggregation, thereby likely contributing to Parkinson"s disease neuropathology. Oxidopamine 169-186 caspase 3 Mus musculus 69-78 12907839-9 2002 VAD-FMK, a broad-spectrum caspase inhibitor, and DEVD-CHO, a potent inhibitor of caspase-3, could block 6-OHDA-induced thymocyte apoptosis. Oxidopamine 104-110 caspase 3 Mus musculus 81-90 12832530-5 2003 Immunoblot and biochemical analysis also confirmed that activation of both caspase-9 and caspase-3 was induced by 6-OHDA, but not by MPP+. Oxidopamine 114-120 caspase 3 Mus musculus 89-98 12832530-6 2003 Consequently, cotreatment with a caspase inhibitor (zVAD-fmk) or with an antioxidant (N-acetylcysteine) not only deterred 6-OHDA-induced loss of TH-positive neurons but also abolished the appearance of activated caspase-3 in TH-positive neurons. Oxidopamine 122-128 caspase 3 Mus musculus 212-221